Putting the award page together from the records…
Putting the award page together from the records…
RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF INJECTABLE NALTREXONE AND MONTHLY INJECTABLE BUPRENORPHINE FOR COCAINE USE DISORDER (CTN-0109). AUGUST 15, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00006 (TO22).
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
1 action since 2024-08-14. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2024-08-14 | 0 | $525.7K | RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF INJECTABLE NALTREXONE AND MONTHLY INJECTABLE BUPRENORPHINE FOR COCAINE USE DISORDER (CTN-0109). AUGUST 15, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00006 (TO22). |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗